As spring temperatures rise along with pollen counts in Georgia, the state is seeing a decline in winter respiratory ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A CDC committee has voted to expand its respiratory syncytial virus vaccine recommendation to include all people aged 50 to ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The CDC’s Advisory Committee on Immunization Practices voted April 16 to expand use of respiratory syncytial virus vaccines among high-risk adults. The updated recommendation calls for a single ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...

This year's flu season has become Washington state's deadliest in nearly a decade, totaling at least 388 deaths so far.

Pfizer (NYSE:PFE) and GSK (NYSE:GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to ...

The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...